Drug intelligence / Profile preview

levonorgestrel + ethinylestradiol (Bayer)

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

Microgynon 21 is a combined oral contraceptive (COC) pill containing two active ingredients: the synthetic progestin **levonorgestrel** (150 mcg) and the synthetic estrogen **ethinylestradiol** (30 mcg). Developed by Bayer, it is indicated for the prevention of pregnancy. The drug works through a multi-faceted mechanism: it suppresses the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, which inhibits the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, thereby preventing ovulation. Additionally, it increases the viscosity of cervical mucus to impede sperm entry and alters the endometrium to reduce the likelihood of implantation. It is typically administered as one tablet daily for 21 consecutive days, followed by a 7-day hormone-free interval to allow for withdrawal bleeding.

Brand names
Microgynon 21Microgynon21Microgynon-21Microgynon
Other names
levonorgestrel/ethinylestradiolethinylestradiol/levonorgestrel
02

Targets

PXR (Pregnane X receptor)PR (Progesterone receptor)ESR1 (ERα)GPER1 (G protein-coupled estrogen receptor 1)GR (Glucocorticoid receptor)SHBG (Sex hormone-binding globulin)ESR2 (ERβ)AR (Adrenergic receptors)

Beyond the preview

Go deeper on levonorgestrel + ethinylestradiol (Bayer).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on levonorgestrel + ethinylestradiol (Bayer).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call